STOCK TITAN

TRACON Pharmaceuticals Inc - TCON STOCK NEWS

Welcome to our dedicated news page for TRACON Pharmaceuticals (Ticker: TCON), a resource for investors and traders seeking the latest updates and insights on TRACON Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRACON Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRACON Pharmaceuticals's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.57%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
TRACON Pharmaceuticals Inc

Nasdaq:TCON

TCON Rankings

TCON Stock Data

19.56M
41.55M
2.6%
11.88%
4.17%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
San Diego

About TCON

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w